Phaseline

Companies › Affinia Therapeutics

Affinia Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AFTX-201
AAV gene therapy delivering BAG3 transgene
BAG3Phase 1Dilated Cardiomyopathy (DCM)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07426419AFTX-201Phase 1Dilated Cardiomyopathy (DCM)CardiovascularDec 2028

Targets

BAG3 (1)

Companies with the same targets

AstraZeneca Rocket Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.